Cargando…

Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation

Cystic fibrosis (CF) is an autosomal recessive disorder, caused by genetic mutations in CF transmembrane conductance regulator protein. Several reports have indicated the presence of specific fatty acid alterations in CF patients, most notably decreased levels of plasmatic and tissue docosahexaenoic...

Descripción completa

Detalles Bibliográficos
Autores principales: Teopompi, Elisabetta, Risé, Patrizia, Pisi, Roberta, Buccellati, Carola, Aiello, Marina, Pisi, Giovanna, Tripodi, Candida, Fainardi, Valentina, Clini, Enrico, Chetta, Alfredo, Rovati, G. Enrico, Sala, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716427/
https://www.ncbi.nlm.nih.gov/pubmed/31507425
http://dx.doi.org/10.3389/fphar.2019.00938
_version_ 1783447373943406592
author Teopompi, Elisabetta
Risé, Patrizia
Pisi, Roberta
Buccellati, Carola
Aiello, Marina
Pisi, Giovanna
Tripodi, Candida
Fainardi, Valentina
Clini, Enrico
Chetta, Alfredo
Rovati, G. Enrico
Sala, Angelo
author_facet Teopompi, Elisabetta
Risé, Patrizia
Pisi, Roberta
Buccellati, Carola
Aiello, Marina
Pisi, Giovanna
Tripodi, Candida
Fainardi, Valentina
Clini, Enrico
Chetta, Alfredo
Rovati, G. Enrico
Sala, Angelo
author_sort Teopompi, Elisabetta
collection PubMed
description Cystic fibrosis (CF) is an autosomal recessive disorder, caused by genetic mutations in CF transmembrane conductance regulator protein. Several reports have indicated the presence of specific fatty acid alterations in CF patients, most notably decreased levels of plasmatic and tissue docosahexaenoic acid (DHA), the precursor of specialized pro-resolving mediators. We hypothesized that DHA supplementation could restore the production of DHA-derived products and possibly contribute to a better control of the chronic pulmonary inflammation observed in CF subjects. Sputum samples from 15 CF and 10 chronic obstructive pulmonary disease (COPD) subjects were collected and analyzed by LC/MS/MS, and blood fatty acid were profiled by gas chromatography upon lipid extraction and transmethylation. Interestingly, CF subjects showed increased concentrations of leukotriene B(4) (LTB(4)), prostaglandin E(2) (PGE(2)), and 15-hydroxyeicosatetraenoic acid (15-HETE), when compared with COPD patients, whereas the concentrations of DHA metabolites did not differ between the two groups. After DHA supplementation, not only DHA/arachidonic acid (AA) ratio and highly unsaturated fatty acid index were significantly increased in the subjects completing the study (p < 0.05) but also a reduction in LTB(4) and 15-HETE was observed, together with a tendency for a decrease in PGE(2,) and an increase in 17-hydroxy-docosahexaenoic acid (17OH-DHA) levels. At the end of the washout period, LTB(4), PGE(2), 15-HETE, and 17OH-DHA showed a trend to return to baseline values. In addition, 15-HETE/17OH-DHA ratio in the same sample significantly decreased after DHA supplementation (p < 0.01) when compared with baseline. In conclusion, our results show here that in CF patients, an impairment in fatty acid metabolism, characterized by increased AA-derived metabolites and decreased DHA-derived metabolites, could be partially corrected by DHA supplementation.
format Online
Article
Text
id pubmed-6716427
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67164272019-09-10 Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation Teopompi, Elisabetta Risé, Patrizia Pisi, Roberta Buccellati, Carola Aiello, Marina Pisi, Giovanna Tripodi, Candida Fainardi, Valentina Clini, Enrico Chetta, Alfredo Rovati, G. Enrico Sala, Angelo Front Pharmacol Pharmacology Cystic fibrosis (CF) is an autosomal recessive disorder, caused by genetic mutations in CF transmembrane conductance regulator protein. Several reports have indicated the presence of specific fatty acid alterations in CF patients, most notably decreased levels of plasmatic and tissue docosahexaenoic acid (DHA), the precursor of specialized pro-resolving mediators. We hypothesized that DHA supplementation could restore the production of DHA-derived products and possibly contribute to a better control of the chronic pulmonary inflammation observed in CF subjects. Sputum samples from 15 CF and 10 chronic obstructive pulmonary disease (COPD) subjects were collected and analyzed by LC/MS/MS, and blood fatty acid were profiled by gas chromatography upon lipid extraction and transmethylation. Interestingly, CF subjects showed increased concentrations of leukotriene B(4) (LTB(4)), prostaglandin E(2) (PGE(2)), and 15-hydroxyeicosatetraenoic acid (15-HETE), when compared with COPD patients, whereas the concentrations of DHA metabolites did not differ between the two groups. After DHA supplementation, not only DHA/arachidonic acid (AA) ratio and highly unsaturated fatty acid index were significantly increased in the subjects completing the study (p < 0.05) but also a reduction in LTB(4) and 15-HETE was observed, together with a tendency for a decrease in PGE(2,) and an increase in 17-hydroxy-docosahexaenoic acid (17OH-DHA) levels. At the end of the washout period, LTB(4), PGE(2), 15-HETE, and 17OH-DHA showed a trend to return to baseline values. In addition, 15-HETE/17OH-DHA ratio in the same sample significantly decreased after DHA supplementation (p < 0.01) when compared with baseline. In conclusion, our results show here that in CF patients, an impairment in fatty acid metabolism, characterized by increased AA-derived metabolites and decreased DHA-derived metabolites, could be partially corrected by DHA supplementation. Frontiers Media S.A. 2019-08-23 /pmc/articles/PMC6716427/ /pubmed/31507425 http://dx.doi.org/10.3389/fphar.2019.00938 Text en Copyright © 2019 Teopompi, Risé, Pisi, Buccellati, Aiello, Pisi, Tripodi, Fainardi, Clini, Chetta, Rovati and Sala http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Teopompi, Elisabetta
Risé, Patrizia
Pisi, Roberta
Buccellati, Carola
Aiello, Marina
Pisi, Giovanna
Tripodi, Candida
Fainardi, Valentina
Clini, Enrico
Chetta, Alfredo
Rovati, G. Enrico
Sala, Angelo
Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation
title Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation
title_full Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation
title_fullStr Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation
title_full_unstemmed Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation
title_short Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation
title_sort arachidonic acid and docosahexaenoic acid metabolites in the airways of adults with cystic fibrosis: effect of docosahexaenoic acid supplementation
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716427/
https://www.ncbi.nlm.nih.gov/pubmed/31507425
http://dx.doi.org/10.3389/fphar.2019.00938
work_keys_str_mv AT teopompielisabetta arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation
AT risepatrizia arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation
AT pisiroberta arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation
AT buccellaticarola arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation
AT aiellomarina arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation
AT pisigiovanna arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation
AT tripodicandida arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation
AT fainardivalentina arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation
AT clinienrico arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation
AT chettaalfredo arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation
AT rovatigenrico arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation
AT salaangelo arachidonicacidanddocosahexaenoicacidmetabolitesintheairwaysofadultswithcysticfibrosiseffectofdocosahexaenoicacidsupplementation